Company Website:
http://www.sppirx.com
HENDERSON, Nev. -- (Business Wire)
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with
fully integrated commercial and drug development operations with a
primary focus in Hematology and Oncology, today announced key
presentations of clinical and scientific data related to its products at
the 59th Annual Meeting of the American Society of Hematology (ASH),
being held in Atlanta, Georgia, from December 9-12, 2017.
For more information about the ASH annual meeting and for a complete
list of abstracts, please refer to the conference website at https://ash.confex.com/ash/2017/webprogram/start.html
The following key PTCL-related abstracts and oral presentations will be
presented at the ASH meeting:
Abstract # |
|
| Type |
|
| Title |
|
| Presenter |
|
| Date/Time Location
|
342 |
|
|
Oral
|
|
|
The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT)
in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete
Remission (CR) with a Special Focus on Nodal PTCL: Report from the
Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma
Treatment (COMPLETE), a Prospective Multicenter Cohort Study
|
|
|
Park
|
|
|
Sunday, Dec 10,
8:45 AM
Bldg B, Lvl 4, B401-402
|
818 |
|
|
Oral
|
|
|
Pralatrexate in Combination with Cyclophosphamide, Doxorubicin,
Vincristine, and Prednisone (CHOP) in Previously Untreated Patients
with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation
Study
|
|
|
Shustov
|
|
|
Monday, Dec 11,
4:45 PM
Bldg A, Lvl 4, Marcus Aud.
|
1455 |
|
|
Poster
|
|
|
North American Adult T Cell Leukemia Lymphoma (ATLL) Is
Characterized By Distinct, Therapeutically Targetable Mutations in
Epigenetic Modifiers
|
|
|
Shah
|
|
|
Saturday, Dec 9,
5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2
|
2743 |
|
|
Poster
|
|
|
Azacytidine and Decitabine Exhibit Differential Effects on
Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci
in Models of Ptcl
|
|
|
Scotto
|
|
|
Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
|
380 |
|
|
Poster
|
|
|
Direct to Drug Screening as a Route to Individualized Therapy in
Multiple Myeloma
|
|
|
Meurice
|
|
|
Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
|
4012 |
|
|
Poster
|
|
|
Histone Deacetylase Inhibitors Abolish HBZ Protein Expression and
Induce Cell Death in HTLV-1 Related Adult T-Cell Leukemia-Lymphoma
|
|
|
Ramos
|
|
|
Monday, Dec 11,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
|
4020 |
|
|
Poster
|
|
|
Selective Inhibition of HDAC1 and HDAC3 Inhibits Survival of Diffuse
Large Cell Lymphoma Via Epigenetic Modulation of Death Associated
Protein (DAPK)
|
|
|
Gupta
|
|
|
Monday, Dec 11
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
|
The following key EVOMELA® (melphalan) for injection-related
abstracts will be presented at the ASH meeting:
Abstract # |
|
| Type |
|
| Title |
|
| Presenter |
|
| Date/Time Location
Bldg A, Lvl 1, Hall A2
|
2023 |
|
|
Poster
|
|
|
Feasibility, Tolerability, and Patient-Reported Outcomes with
Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol
free melphalan) for Multiple Myeloma and AL Amyloidosis Patients
Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)
|
|
|
Shah
|
|
|
Saturday, Dec 9,
5:30 PM-7:30 PM
|
3296 |
|
|
Poster
|
|
|
Pharmacokinetics and Toxicities after Evomela® (propylene
glycol free melphalan) with Autologous Hematopoietic Stem Cell
Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis
|
|
|
Shah
|
|
|
Sunday, Dec 10,
6:00 PM-8:00 PM
|
The following key MARQIBO® (vinCRIStine sulfate LIPOSOME
injection)-related abstracts will be presented at the ASH meeting:
Abstract # |
|
| Type |
|
| Title |
|
| Presenter |
|
| Date/Time Location
Bldg A, Lvl 1, Hall A2
|
1549 |
|
|
Poster
|
|
|
Excellent Outcome of Elderly Patients with Favourable-Prognosis
DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of
Rituximab and a PET-Based Intensification Strategy That Includes
Involved-Site Radiotherapy (IS-RT): Results of the First 120
Patients of the OPTIMAL>60 Trial of the Dshnhl
|
|
|
Pfreundschuh
|
|
|
Saturday, Dec 9,
5:30 PM-7:30 PM
|
1328 |
|
|
Poster
|
|
|
Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in
Real-World US Practices
|
|
|
LeBlanc
|
|
|
Saturday, Dec 9,
5:30 PM-7:30 PM
|
2554 |
|
|
Poster
|
|
|
Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo)
for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
|
|
|
Sasaki
|
|
|
Sunday, Dec 10,
6:00 PM-8:00 PM
|
The following key ZEVALIN® (ibritumomab tiuxetan)-related
abstracts will be presented at the ASH meeting:
Abstract # |
|
| Type |
|
| Title |
|
| Presenter |
|
| Date/Time Location
Bldg A, Lvl 1, Hall A2
|
1553 |
|
|
Poster
|
|
|
A Phase II Intergroup Trial of PET-Directed Therapy for Limited
Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001
(NCT01359592)
|
|
|
Persky
|
|
|
Saturday, Dec 9,
5:30 PM-7:30 PM
|
4559 |
|
|
Poster
|
|
|
Long-Term Follow up of 90y-Ibritumomab Tiuxetan,
Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant
Conditioning for Persistent High-Risk B-Cell Lymphoma
|
|
|
Puronen
|
|
|
Monday, Dec 11,
6:00 PM-8:00 PM
|
4066 |
|
|
Poster
|
|
|
Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with
Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A
Single-Institution Experience
|
|
|
Agrawal
|
|
|
Monday, Dec 11,
6:00 PM-8:00 PM
|
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology Company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in Hematology and Oncology. Spectrum currently markets six
hematology/oncology drugs, and has an advanced stage pipeline that has
the potential to transform the Company. Spectrum's strong track record
for in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.These
statements are based on management's current beliefs and expectations.These statements include, but are not limited to, statements that
relate to Spectrum’s business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, the timing and results of FDA decisions, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact.Risks that could cause actual results to differ include the
possibility that Spectrum’s existing and new drug candidates may not
prove safe or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not receive
approval in a timely manner or at all, the possibility that our existing
and new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates
may fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks that are
described in further detail in the Company's reports filed with the
Securities and Exchange Commission.The Company does not plan to
update any such forward-looking statements and expressly disclaims any
duty to update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.®, ZEVALIN®,
MARQIBO®, BELEODAQ®,
EVOMELA® are registered trademarks of Spectrum
Pharmaceuticals, Inc. and its affiliates.REDEFINING CANCER CARE™
and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum
Pharmaceuticals, Inc.Any other trademarks are the property of
their respective owners.
© 2017 Spectrum Pharmaceuticals, Inc.All Rights Reserved
View source version on businesswire.com: http://www.businesswire.com/news/home/20171204005127/en/
Contacts:
Spectrum Pharmaceuticals
Shiv Kapoor
Vice President, Strategic
Planning & Investor Relations
702-835-6300
InvestorRelations@sppirx.com
Source: Spectrum Pharmaceuticals
© 2024 Canjex Publishing Ltd. All rights reserved.